Department of Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Division of Medical Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA.
Curr Oncol Rep. 2022 Nov;24(11):1413-1423. doi: 10.1007/s11912-022-01302-3. Epub 2022 Jun 3.
For patients with malignant pleural mesothelioma, prognosis is poor with extremely low 5-year survival rates and limited therapeutic options. Here, we review the current treatment landscape for mesothelioma and highlight promising future therapeutic directions.
Evolving frontline therapeutic options for mesothelioma include VEGF inhibition in combination with chemotherapy and dual immune checkpoint inhibition, with synergisms between the therapies and response prediction via biomarkers also being explored. Evolving experimental treatments for mesothelioma include PARP and ALK inhibitors, dendritic and CAR T-cell therapies, anti-mesothelin vaccines, and oncolytic viral therapies, representing timely advances in the field. The therapeutic landscape for malignant pleural mesothelioma is evolving and preferred treatment in the frontline and later settings will likely evolve with it. However, this does not preclude the evidence for including multi-modal therapies spanning angiogenesis and immune checkpoint inhibitors, and biomarker utilization, in current clinical trials and management.
对于恶性胸膜间皮瘤患者，预后极差，5 年生存率极低，治疗选择有限。在此，我们综述间皮瘤的当前治疗现状，并强调有前途的未来治疗方向。
间皮瘤的一线治疗选择包括 VEGF 抑制联合化疗和双重免疫检查点抑制，同时还在探索治疗协同作用和通过生物标志物进行反应预测。间皮瘤的不断发展的实验性治疗方法包括 PARP 和 ALK 抑制剂、树突状和 CAR T 细胞疗法、抗间皮素疫苗和溶瘤病毒疗法，这代表了该领域的及时进展。恶性胸膜间皮瘤的治疗现状正在不断发展，一线和后续治疗的首选治疗方法可能会随之发展。然而，这并不排除将跨越血管生成和免疫检查点抑制剂以及生物标志物应用的多模式治疗纳入当前临床试验和管理的证据。
